207 related articles for article (PubMed ID: 31132401)
41. Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
Goteti K; Garner CE; Utley L; Dai J; Ashwell S; Moustakas DT; Gönen M; Schwartz GK; Kern SE; Zabludoff S; Brassil PJ
Cancer Chemother Pharmacol; 2010 Jul; 66(2):245-54. PubMed ID: 19841922
[TBL] [Abstract][Full Text] [Related]
42. Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis.
Singh R; Peng S; Viswanath P; Sambandam V; Shen L; Rao X; Fang B; Wang J; Johnson FM
EMBO Mol Med; 2019 May; 11(5):. PubMed ID: 31040125
[TBL] [Abstract][Full Text] [Related]
43. CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model.
Campagne O; Davis A; Maharaj AR; Zhong B; Stripay J; Farmer D; Roussel MF; Stewart CF
Eur J Pharm Sci; 2020 Jan; 142():105106. PubMed ID: 31669383
[TBL] [Abstract][Full Text] [Related]
44. Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.
Srivastava AK; Hollingshead MG; Govindharajulu JP; Covey JM; Liston D; Simpson MA; Peggins JO; Bottaro DP; Wright JJ; Kinders RJ; Doroshow JH; Parchment RE
Mol Cancer Ther; 2018 Mar; 17(3):698-709. PubMed ID: 29444985
[TBL] [Abstract][Full Text] [Related]
45. Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods.
Song L; Yao X; Liu Y; Zhong W; Jiang J; Liu H; Zhou H; Shi C; Zong K; Wang C; Ma C; Liu D; Hu P
Eur J Pharm Sci; 2020 Apr; 147():105281. PubMed ID: 32126254
[TBL] [Abstract][Full Text] [Related]
46. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
[TBL] [Abstract][Full Text] [Related]
47. A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib.
Tosca EM; Terranova N; Stuyckens K; Dosne AG; Perera T; Vialard J; King P; Verhulst T; Perez-Ruixo JJ; Magni P; Poggesi I
Cancer Chemother Pharmacol; 2022 Jan; 89(1):117-128. PubMed ID: 34786600
[TBL] [Abstract][Full Text] [Related]
48. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
[TBL] [Abstract][Full Text] [Related]
49. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
[TBL] [Abstract][Full Text] [Related]
50. Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer.
Lu J; Li G; He K; Jiang W; Xu C; Li Z; Wang H; Wang W; Wang H; Teng X; Teng L
J Transl Med; 2015 Feb; 13():42. PubMed ID: 25638174
[TBL] [Abstract][Full Text] [Related]
51. A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques.
Titze MI; Schaaf O; Hofmann MH; Sanderson MP; Zahn SK; Quant J; Lehr T
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1303-14. PubMed ID: 27160688
[TBL] [Abstract][Full Text] [Related]
52. Pharmacodynamics-based approach for efficacious human dose projection of BMS-986260, a small molecule transforming growth factor beta receptor 1 inhibitor.
Parrish KE; Swanson J; Cheng L; Luk E; Stetsko P; Smalley J; Shu YZ; Huang J; Pabalan JG; Sun Y; Zvyaga T; Cvijic ME; Burke J; Borzilleri R; Murtaza A; Augustine K; Yang Z
Biopharm Drug Dispos; 2021 Apr; 42(4):137-149. PubMed ID: 33354831
[TBL] [Abstract][Full Text] [Related]
53. Semi-Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for the Combination Use of Dexamethasone and Gemcitabine in Breast Cancer.
Yuan Y; Zhou X; Ren Y; Zhou S; Wang L; Ji S; Hua M; Li L; Lu W; Zhou T
J Pharm Sci; 2015 Dec; 104(12):4399-4408. PubMed ID: 26344053
[TBL] [Abstract][Full Text] [Related]
54. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
[TBL] [Abstract][Full Text] [Related]
55. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
Wu DW; Chen TC; Huang HS; Lee H
Cell Death Dis; 2016 Jun; 7(6):e2290. PubMed ID: 27362807
[TBL] [Abstract][Full Text] [Related]
56. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
Hay MP; Hicks KO; Pruijn FB; Pchalek K; Siim BG; Wilson WR; Denny WA
J Med Chem; 2007 Dec; 50(25):6392-404. PubMed ID: 18001018
[TBL] [Abstract][Full Text] [Related]
59. Predicting Antitumor Effect of Deoxypodophyllotoxin in NCI-H460 Tumor-Bearing Mice on the Basis of In Vitro Pharmacodynamics and a Physiologically Based Pharmacokinetic-Pharmacodynamic Model.
Chen Y; Zhao K; Liu F; Li Y; Zhong Z; Hong S; Liu X; Liu L
Drug Metab Dispos; 2018 Jun; 46(6):897-907. PubMed ID: 29618575
[TBL] [Abstract][Full Text] [Related]
60. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.
Zhao F; Zhang LD; Hao Y; Chen N; Bai R; Wang YJ; Zhang CC; Li GS; Hao LJ; Shi C; Zhang J; Mao Y; Fan Y; Xia GX; Yu JX; Liu YJ
Eur J Med Chem; 2017 Jul; 134():147-158. PubMed ID: 28411455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
